|
1. Biologie
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.3 Dép., diag. & prono. - Industriels
|
|
|
Amgen sharpens focus on genetic sequencing with $66M investment [EndPoints]
|
|
|
|
|
|
“Oxford
Nanopore’s long-read sequencing capability creates a window into parts
of the genome that have been out of reach, as well as giving us a much
better handle on structural variants that confer risk of a wide variety
of diseases,” said Kári Stefánsson, founder of Amgen subsidiary deCODE
Genetics, which has been using Oxford Nanopore’s technology.
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
Fighting Cancer with Natural Killer Cells [NIH Director's Blog]
|
|
|
|
|
|
The
video shows an army of NK cells (green) attacking a tumor in a mouse
(blood vessels, blue) treated with a well-established type of cancer
immunotherapy known as a checkpoint inhibitor. What makes the video so
interesting is that researchers didn’t think checkpoint inhibitors could
activate NK cells.
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
5.6.16 ESMO - Appareil digestif
|
|
|
|
5.6.17 ESMO - Foie
|
|
|
|
5.6.6 ESMO - Sein
|
|
|
|
6. Lutte contre les cancers
|
|
|
Project Baseline Aims to Ward Off Illness Before We Get Sick [NY Times]
|
|
|
|
|
|
The
study, called Project Baseline, is a joint effort between Stanford and
Duke Universities and Verily, a life sciences company owned by Alphabet,
the parent company of Google. Researchers are recruiting 10,000 adults
across the United States who will be examined in extreme detail and
followed intensively for at least four years.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
New Statistical Method Estimates Time to Metastasis of Breast Cancer in U.S. Women [AACR]
|
|
|
|
|
|
The
study found that while women diagnosed with HR-positive breast cancer
have lower risk of progression to metastatic disease soon after the
diagnosis, their risk persists for several years. In contrast, for women
diagnosed with HR-negative disease, the risk of progression to
metastatic disease is high soon after the diagnosis, but the long-term
risk is lower than that for HR-positive disease.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
Researchers, cancer patients, and philanthropists launch "Count Me In" [Broad Institute]
|
|
|
|
|
|
Count
Me In is being stewarded by four leading organizations: Emerson
Collective, a California-based social change organization; Broad
Institute of MIT and Harvard, a leading nonprofit biomedical research
institution; the Biden Cancer Initiative, an independent nonprofit
organization that builds on the federal government’s Cancer Moonshot;
and the Dana-Farber Cancer Institute, a leading cancer hospital.
|
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|